Core Viewpoint - Pfizer's new drug Marstacimab injection has received acceptance for a new indication to treat bleeding tendencies in patients with congenital hemophilia who have inhibitors to coagulation factors VIII or IX, classified as a 2.2 category registration by the National Medical Products Administration (NMPA) [1][3]. Group 1: Drug Information - Marstacimab (PF-6741086) is a monoclonal antibody targeting the K2 domain of tissue factor pathway inhibitor (TFPI), which plays a role in hemostasis and thrombus prevention [2]. - The drug has been approved in the US, EU, Japan, and China for treating severe hemophilia A and B in patients aged 12 and older, weighing at least 35 kg, to reduce bleeding episodes [3]. - Marstacimab is the first subcutaneous injection for hemophilia B that requires administration only once a week and is the first fixed-dose regimen for both hemophilia A and B [3]. Group 2: Regulatory and Market Developments - Pfizer announced the formal approval of Marstacimab in China in November 2025, marking a significant milestone for the drug's market presence [2]. - The new indication for Marstacimab was officially accepted by the CDE, indicating progress in expanding its therapeutic applications [3].

Core Insights - The report recommends focusing on the CXO sector within the pharmaceutical and biotechnology industry, highlighting its global competitiveness and long-term growth potential [6][4] - The investment strategy maintains an "outperform" rating for the sector, with a specific portfolio of recommended stocks for December 2025 [2][6] Industry Overview - The pharmaceutical manufacturing industry saw a cumulative revenue of 199.55 billion yuan from January to October 2025, reflecting a year-on-year decline of 2.9%, while total profits decreased by 3.5% to 26.98 billion yuan [10][9] - The retail sales of Western and Chinese medicines reached 595.5 billion yuan, with a modest growth of 1.5% year-on-year [10][9] Investment Strategy - The recommended investment portfolio for December 2025 includes notable A-shares such as Mindray Medical (迈瑞医疗), WuXi AppTec (药明康德), and Aier Eye Hospital (爱尔眼科), among others [6][7] - The report emphasizes the importance of monitoring the clinical progress and data readouts of innovative drugs in overseas markets, as these factors can enhance the commercial viability of domestic products [6] Market Performance - The pharmaceutical sector experienced a decline of 3.62% in November 2025, underperforming the CSI 300 index by 1.16% [11] - The medical services sub-sector faced the most significant drop, with a decrease of 7.77%, while the pharmaceutical commercial sector saw a slight increase of 1.27% [17][11] Valuation Insights - The overall valuation of the pharmaceutical sector is relatively high, with a current PE (TTM) of 37.71, placing it at the 79.87 percentile of its historical range over the past five years [19][20] - The premium rates of the pharmaceutical sector compared to the CSI 300 and the entire A-share market remain at historical averages [19][20] Recent Developments - In November 2025, eight innovative drugs or biosimilars were approved for market entry, including products from Pfizer and domestic companies, indicating a robust pipeline for new therapies [25][26] - The report tracks the NDA and IND applications for innovative drugs, highlighting ongoing research and development activities within the industry [27][28]